Published in J Virol on August 01, 1999
A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity. J Virol (2001) 1.80
Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly. J Virol (2001) 1.38
Specific interaction of a novel foamy virus Env leader protein with the N-terminal Gag domain. J Virol (2001) 1.24
Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids. J Virol (2002) 1.22
RNA and protein requirements for incorporation of the Pol protein into foamy virus particles. J Virol (2005) 1.20
Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging. J Virol (2000) 1.18
Mutation of the catalytic domain of the foamy virus reverse transcriptase leads to loss of processivity and infectivity. J Virol (2002) 1.15
Characterization of the polymerase and RNase H activities of human foamy virus reverse transcriptase. J Virol (2004) 1.15
Human foamy virus capsid formation requires an interaction domain in the N terminus of Gag. J Virol (2001) 1.05
Protease-dependent uncoating of a complex retrovirus. J Virol (2005) 1.00
Role of the foamy virus Pol cleavage site in viral replication. J Virol (2007) 1.00
Cell-type-specific regulation of the two foamy virus promoters. J Virol (2001) 1.00
Foamy virus envelope glycoprotein is sufficient for particle budding and release. J Virol (2003) 0.93
Foamy virus Pol protein expressed as a Gag-Pol fusion retains enzymatic activities, allowing for infectious virus production. J Virol (2012) 0.81
Foamy virus Gag p71-p68 cleavage is required for template switch of the reverse transcriptase. J Virol (2013) 0.76
Using hyperLOPIT to perform high-resolution mapping of the spatial proteome. Nat Protoc (2017) 0.75
The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol (1990) 5.19
Novel mechanism for reverse transcription in hepatitis B viruses. J Virol (1993) 4.47
Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J (1992) 3.78
An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol (1993) 3.72
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science (1996) 3.25
Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J Virol (1994) 3.05
Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci U S A (1996) 2.97
Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J (1997) 2.91
Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology (1993) 2.81
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol (1997) 2.42
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Foamy virus reverse transcriptase is expressed independently from the Gag protein. Proc Natl Acad Sci U S A (1996) 2.22
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol (1993) 2.18
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol (1999) 2.15
Translational suppression in retroviral gene expression. Adv Virus Res (1992) 1.93
Evidence that the human foamy virus genome is DNA. J Virol (1999) 1.85
The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol (1998) 1.82
Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol (1995) 1.81
The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein. J Virol (1996) 1.74
Spumaviruses: a group of complex retroviruses. J Acquir Immune Defic Syndr (1991) 1.64
Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle. J Virol (1997) 1.57
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli. J Virol (1986) 1.55
Molecular cloning of the genome of human spumaretrovirus. Gene (1987) 1.52
Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites. Nucleic Acids Res (1992) 1.50
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46
trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase. J Virol (1991) 1.45
RNA dependent DNA polymerase in primate syncytium-forming (foamy) viruses. Nature (1971) 1.42
Molecular characterization of proteolytic processing of the Pol proteins of human foamy virus reveals novel features of the viral protease. J Virol (1998) 1.24
Reverse transcriptase from simian foamy virus serotype 1: purification and characterization. J Virol (1982) 1.19
Molecular biological characterization of the human foamy virus reverse transcriptase and ribonuclease H domains. Virology (1995) 1.18
Sequences in pol are required for transfer of human foamy virus-based vectors. J Virol (1998) 1.15
Expression and characterization of hepadnavirus reverse transcriptases. Methods Enzymol (1996) 1.12
Translational regulation of hepatitis B virus polymerase gene by termination-reinitiation of an upstream minicistron in a length-dependent manner. J Gen Virol (1998) 1.08
A generic method for expression and use of "tagged" soluble versions of cell surface receptors. Biotechnology (N Y) (1995) 0.99
Mutational analysis of the reverse transcriptase and ribonuclease H domains of the human foamy virus. Nucleic Acids Res (1995) 0.96
Reverse transcriptase of foamy virus. Purification of the enzymes and immunological identification. Arch Virol (1977) 0.94
Characterization of RNase H activity associated with reverse transcriptase in simian foamy virus type 1. J Virol (1983) 0.86
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science (1996) 3.25
Avian retroviral RNA encapsidation: reexamination of functional 5' RNA sequences and the role of nucleocapsid Cys-His motifs. J Virol (1993) 2.52
Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J Virol (1994) 2.21
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol (1993) 2.18
Historical perspective of foamy virus epidemiology and infection. Clin Microbiol Rev (2001) 2.08
The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains. J Virol (1996) 1.91
Evidence that the human foamy virus genome is DNA. J Virol (1999) 1.85
The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol (1998) 1.82
Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem (1996) 1.46
Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly. J Virol (2001) 1.38
Specific binding of human immunodeficiency virus type 1 (HIV-1) Gag-derived proteins to a 5' HIV-1 genomic RNA sequence. J Virol (1996) 1.36
A model system for nonhomologous recombination between retroviral and cellular RNA. J Virol (1993) 1.32
Unusual features of integrated cDNAs generated by infection with genome-free retroviruses. Mol Cell Biol (1990) 1.32
Modification of retroviral RNA by double-stranded RNA adenosine deaminase. J Virol (1995) 1.31
Foamy virus infection in primates. J Med Primatol (2006) 1.23
The human foamy virus internal promoter is required for efficient gene expression and infectivity. Virology (1995) 1.23
Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression. J Virol (2006) 1.23
A minimal avian retroviral packaging sequence has a complex structure. J Virol (1998) 1.20
Multiple integrations of human foamy virus in persistently infected human erythroleukemia cells. J Virol (2000) 1.14
Secondary structure analysis of a minimal avian leukosis-sarcoma virus packaging signal. J Virol (2000) 1.12
Productive persistent infection of hematopoietic cells by human foamy virus. J Virol (1996) 1.12
Molecular cloning and characterization of the RNA packaging-defective retrovirus SE21Q1b. J Virol (1992) 1.09
An Mpsi-containing heterologous RNA, but not env mRNA, is efficiently packaged into avian retroviral particles. J Virol (1999) 1.07
Tissue-specific lability and expression of avian leukosis virus long terminal repeat enhancer-binding proteins. Mol Cell Biol (1989) 1.05
Cell-type-specific regulation of the two foamy virus promoters. J Virol (2001) 1.00
The gag domains required for avian retroviral RNA encapsidation determined by using two independent assays. J Virol (1999) 0.99
The packaging phenotype of the SE21Q1b provirus is related to high proviral expression and not trans-acting factors. J Virol (1995) 0.97
gag as well as myc sequences contribute to the transforming phenotype of the avian retrovirus FH3. J Virol (1992) 0.92
Endogenous virus of BHK-21 cells complicates electron microscopy studies of foamy virus maturation. J Virol (1999) 0.89
FH3, a v-myc avian retrovirus with limited transforming ability. J Virol (1989) 0.88
Transforming variants of the avian myc-containing retrovirus FH3 arise prior to phenotypic selection. J Virol (1993) 0.87
Transforming ability of Gag-Myc fusion proteins correlates with Gag-Myc protein stability and transcriptional repression. Oncogene (2001) 0.87
Yeast three-hybrid screening of rous sarcoma virus mutants with randomly mutagenized minimal packaging signals reveals regions important for gag interactions. J Virol (2000) 0.86
Overproduction of v-Myc in the nucleus and its excess over Max are not required for avian fibroblast transformation. Mol Cell Biol (1993) 0.85
v-Myc is invariably required to sustain rapid proliferation of infected cells but in stable cell lines becomes dispensable for other traits of the transformed phenotype. Oncogene (1995) 0.77
Tail-to-head arrangement of a partial chicken glyceraldehyde-3-phosphate dehydrogenase processed pseudogene. J Mol Evol (1997) 0.77
Characterization of a unique retroviral recombinant containing 7S L sequences. J Virol (1993) 0.77
Retrotransposition of nonviral RNAs in an avian packaging cell line. J Virol (1998) 0.77
Inhibition of wild-type HIV-1 virus production by a matrix deficient Gag mutant. Virology (1995) 0.75